MorphoSys AG (MOR.DE)

67,85 +0,10 (+0,15%) Al cierre: 05:36PM CEST

MorphoSys AG

Semmelweisstrasse 7
Planegg 82152
Germany
49 89 899 27-0
https://www.morphosys.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 524

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Jean-Paul Kress M.D.	Chairman of Management Board, MD & CEO	1,76M	N/A	1965
Dr. Lucinda Crabtree Ph.D.	CFO & Member of Management Board	705,82k	N/A	1979
Ms. Charlotte Lohmann	Chief Legal and Human Resources Officer & Member of Management Board	474,1k	N/A	1970
Mr. Klaus De Wall	Head of Accounting & Tax	N/A	N/A	N/A
Dr. Margit Urban	Head of Discovery Alliances & Technologies	N/A	N/A	N/A
Dr. Julia Neugebauer Ph.D.	Head of Investor Relations	N/A	N/A	N/A
Dr. Barbara Krebs-Pohl Ph.D.	Chief Business Officer	N/A	N/A	N/A
Dr. Günter Wellnhofer	Head of Technical Operations	N/A	N/A	N/A
Dr. Harald Watzka	Head of Alliance Management	N/A	N/A	N/A
Ms. Yen Ching Chua	Head of Clinical Operations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Gobierno corporativo

El ISS Governance QualityScore de MorphoSys AG, a día 1 de abril de 2024, es 2. Las puntuaciones base son Auditoría: 2; Tablero: 1; Derechos de los accionistas: 1; Compensación: 6.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.